JC
BOLD

JBF Capital’s Audentes Therapeutics, Inc BOLD Stock Holding History

JBF Capital’s Portfolio BOLD Stock Details BOLD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q4 		– Sell
-31,300
Closed -$1.24M – 176
2018
Q3 		$1.24M Hold
31,300
– – 0.18% 25
2018
Q2 		$1.2M Buy
31,300
+10,000
+47% +$370K 0.18% 37
2018
Q1 		$640K Buy
+21,300
New +$721K 0.1% 50

Other funds holding BOLD

Wellington Management Group
Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return
PHS
PFM Health Sciences San Francisco, California $1.1B AUM 57.92% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
RG
Redmile Group San Francisco, California $1.51B AUM 164.17% 1-Year Est. Return
O
OrbiMed New York $5.05B AUM 125.28% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
GPP
Great Point Partners Greenwich, Connecticut $435M AUM 318.81% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
VVM
Versant Venture Management San Francisco, California $141M AUM 190.82% 1-Year Est. Return

JBF Capital's BOLD Position: Q4 2018 in Review

JBF Capital sold out of Audentes Therapeutics, Inc (BOLD) in Q4 2018, closing a stake of 31,300 shares — an estimated $1.24M sold.

JBF Capital first reported a position in BOLD in Q1 2018 and held it in 3 quarters. The position peaked at $1.24M in Q3 2018. 126 funds tracked by Wall St. Rank hold BOLD as of Q4 2018.

  • JBF Capital reported no remaining Audentes Therapeutics, Inc position as of Q4 2018 after selling out during the quarter.
  • JBF Capital sold 31,300 Audentes Therapeutics, Inc shares in Q4 2018, an estimated $1.24M.
  • JBF Capital first reported a position in Audentes Therapeutics, Inc in Q1 2018 and held it in 3 quarters.
  • JBF Capital's Audentes Therapeutics, Inc position peaked at $1.24M in Q3 2018.
  • 126 funds tracked by Wall St. Rank held Audentes Therapeutics, Inc as of Q4 2018.

Based on JBF Capital's 13F filing for Q4 2018, filed 12 Feb 2019.